For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Semaglutide

Also known as: Semaglutide (GLP-1 agonist)

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.

Real-time market data

Pricing for Semaglutide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$9.28/mg

range $1.00–$44.70/mg

Sellers

62

from $0.00

45-day trend

+23.4%

vs 45-day avg $/mg

54 of 62 sellers have a current price· 42 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Semaglutide

153 third-party tests across 20 vendors. Each card links to the full report.

All 153 COAs for Semaglutide →
Measured purity 99.0%–100.0% across 97 COAs
Measured purity over time
✓ Vendor-published
99.94 %
Jun 2026
TrustPointe Analytics Moderate

For

Semaglutide

by Peptide Partners· batch SPL-4149

COA on file
Aggregated · 3rd-party listing
99.07 %
Jun 2026
ILS Labs Strong

For

Semaglutide

by Peptide Plugs· batch 125-01-SM

Aggregated · 3rd-party listing
99.75 %
May 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1005102026-03

✓ Vendor-published
99.63 %
May 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1005102026-03

COA on file
Aggregated · 3rd-party listing
99.23 %
May 2026
Horizon Analytical

For

Semaglutide

by Pepsgpt· batch P-2885342-P

Aggregated · 3rd-party listing
99.86 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3022026SM

Aggregated · 3rd-party listing
99.75 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3142026SM

Aggregated · 3rd-party listing
99.17 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 2242026SM

✓ Vendor-published
99.96 %
Apr 2026
Kovera Labs

For

ION-1S

by Ion Peptide· batch ION1S20-04172026

COA on file
Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

Semaglutide

by OROS Research· batch OR-LPGLPS10-426-B3

Aggregated · 3rd-party listing
99.68 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3272026SM

Aggregated · 3rd-party listing
99.63 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3222026SX

Aggregated · 3rd-party listing
99.80 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

Semaglutide

by Blank Peptides· batch 665394

Aggregated · 3rd-party listing
99.41 %
Mar 2026
AccumarkLabs Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 2182026SM

Aggregated · 3rd-party listing
99.02 %
Mar 2026
Vanguard Laboratory Strong · HPLC

For

Semaglutide

by Prime Peptides· batch 2122026SM

Aggregated · 3rd-party listing
99.83 %
Mar 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Orbitrex Peptides· batch 1G200426

Aggregated · 3rd-party listing
99.45 %
Mar 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Qihang Peptide· batch 3

✓ Vendor-published
99.76 %
Feb 2026
Vanguard Laboratory Strong

For

Semaglutide

by Reta One Labs· batch SM100326

COA on file
✓ Vendor-published
99.31 %
Feb 2026
Vanguard Laboratory Strong

For

Semaglutide

by Reta One Labs· batch SM200326

COA on file
Aggregated · 3rd-party listing
99.81 %
Feb 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P0502152026-01

✓ Vendor-published
99.81 %
Feb 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P0502152026-01

COA on file
Aggregated · 3rd-party listing
99.76 %
Feb 2026
Vanguard Laboratory Strong · HPLC

For

Semaglutide

by Reta One Labs· batch SM100326

Aggregated · 3rd-party listing
99.31 %
Feb 2026
Vanguard Laboratory Strong · HPLC

For

Semaglutide

by Reta One Labs· batch SM200326

Aggregated · 3rd-party listing
99.52 %
Feb 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 1052026SM

Research depth

23 citations indexed for Semaglutide

All research on Semaglutide →

Study · 2026

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Background This phase 2 study evaluated once-weekly zalfermin and semaglutide for efficacy and safety in patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, including patients with compensated cirrhosis (F4c).

animal · 2026

Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, effectively promotes weight loss and improves metabolic parameters in individuals with obesity. However, its use is often accompanied by reductions in lean mass, raising concerns about long-term muscle health.

cohort · 2026

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials

Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.

Study · 2026

Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists

Aims Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus (T2DM) and obesity. However, whether risks differ across successive generations of incretin-based therapies remains uncertain.

Study · 2026

Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes

This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type 2 diabetes and overweight or obesity. The findings showed significantly lower risks of both outcomes compared with DPP-4 inhibitors.

Study · 2026

Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes

Aim In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre-marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed.